CoChat

GPER in metabolic homeostasis and disease: molecular mechanisms, nutritional regulation, and therapeutic potential

Open access
Liu, Liyan, Zhou, Yutao, Liu, Jing, Zhang, Xinmiao, He, Chongwu, Zeng, Xiaoqiang, Dejenie, Rebeka, Zeb, Usman, Zeng, Qiao, Liu, Lan, Li, Jianglong, Zeng, Xingsheng, Hu, Qinglong, Huang, Xianming, Xu, Xue, Dong, Hanzhi, Zhong, Jinxiu, Huang, Yanxiao, Lv, Qiaoli, Liu, Bo, Qiu, Yu-an, Yu, Tenghua · 2025 · Journal of Translational Medicine

The DOI matches its Crossref record; 286 of the 286 references it cites were found in a registry or an index.

Abstract

G protein-coupled estrogen receptor (GPER) significantly influences metabolic regulation by engaging multiple signaling pathways that affect overall metabolic health. Its structure and signaling mechanisms drive its diverse roles. Our team and others have successfully demonstrated that GPER modulates nutrient metabolism, spanning glucose, protein, and lipid metabolism, while also contributing to vitamin and mineral metabolism. Studies have linked GPER to metabolic disorders, including type 2 diabetes, nonalcoholic fatty liver disease, metabolic syndrome, and cardiovascular diseases, as well as thyroid disorders, highlighting its wide-reaching metabolic impact. GPER holds promise for energy balance and weight management by regulating energy expenditure and thermogenesis. Moreover, it appears to influence the metabolism of cancer cells during tumor progression. Rapid advancements in GPER agonist and antagonist research have highlighted the therapeutic potential of GPER agonists for treating metabolic diseases. Further investigations into GPER biology, mechanisms, and clinical applications will support novel therapeutic strategies, establishing GPER as a key target in metabolic research and treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-025-07005-0

Cites

286 of 286 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic representation of the GPER structure. The diagram illustrates the canonical architecture of GPER, a member of the GPCR family. The key structural features include the following: (1) seven transmembrane domains (TM1-TM7) that form a ligand-binding pocket within the cell membrane, (2) the extracellular N-terminal domain that binds ligands such as estrogen and initiates signal transduction, and (3) the intracellular C-terminal region coupled to heterotrimeric G proteins, which mediate downstream signaling cascades
Fig. 1 Schematic representation of the GPER structure. The diagram illustrates the canonical architecture of GPER, a member of the GPCR family. The key structural features include the following: (1) seven transmembrane domains (TM1-TM7) that form a ligand-binding pocket within the cell membrane, (2) the extracellular N-terminal domain that binds ligands such as estrogen and initiates signal transduction, and (3) the intracellular C-terminal region coupled to heterotrimeric G proteins, which mediate downstream signaling cascadesCC BY-NC-ND · PubMed Central
Fig. 2 Mechanism of GPER signal transduction. GPER is present mainly on the cell membrane. Upon binding to GPER agonists, it activates heterotrimeric G proteins, which initiate multiple signaling pathways. The pathways include the activation of AC, which generates cAMP, and subsequently, elevated cAMP levels trigger PKA-mediated substrate phosphorylation. GPER activation also affects the PI3K-AKT-mTOR and MAPK-ERK pathways. PLC is activated, cleaving PIP2 into inositol IP3 and DAG. IP3 binds endoplasmic reticulum receptors to rapidly mobilize calcium. Meanwhile, DAG activates PKC. Additionally, GPER can interact with the LKB1-CaMKKβ-AMPK pathway. AMPK also upregulates CPT1 and PPARα and downregulates FAS and SREBP-1c. In the nucleus, GPER acts like ERα and ERβ, modulating transcription factors such as CREB, Nrf2, and NF-κB and influencing the expression of cytokines such as TNF-α, IL-1β, and IL-6. GPER antagonists can block these signaling processes. Abbreviations: GPER, G protein-coupled estrogen receptor; AC, adenylyl cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; PLC, phospholipase C; PPI2, phosphatidylinositol-4,5-bisphosphate; IP3, inositol trisphosphate; DAG, diacylglycerol; PKC, protein kinase C; LKB1, liver kinase B1; CaMKKβ, calmodulin-dependent protein kinase kinase beta; AMPK, AMP-activated protein kinase; CPT1, carnitine palmitoyl transferase 1; PPARα, peroxisome proliferator-activated receptor alpha; FAS, fatty acid synthase; SREBP-1 C, sterol regulatory element-binding protein 1c; GLUT4, glucose transport protein 4; ERα, estrogen receptor α; ERβ, estrogen receptor β; CREB, cAMP-response element binding protein; Nrf2, nuclear factor erythroid 2-related factor 2; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; TNF-α, tumor necrosis factor alpha; IL-1β, interleukin-1 beta; IL-6, interleukin-6
Fig. 2 Mechanism of GPER signal transduction. GPER is present mainly on the cell membrane. Upon binding to GPER agonists, it activates heterotrimeric G proteins, which initiate multiple signaling pathways. The pathways include the activation of AC, which generates cAMP, and subsequently, elevated cAMP levels trigger PKA-mediated substrate phosphorylation. GPER activation also affects the PI3K-AKT-mTOR and MAPK-ERK pathways. PLC is activated, cleaving PIP2 into inositol IP3 and DAG. IP3 binds endoplasmic reticulum receptors to rapidly mobilize calcium. Meanwhile, DAG activates PKC. Additionally, GPER can interact with the LKB1-CaMKKβ-AMPK pathway. AMPK also upregulates CPT1 and PPARα and downregulates FAS and SREBP-1c. In the nucleus, GPER acts like ERα and ERβ, modulating transcription factors such as CREB, Nrf2, and NF-κB and influencing the expression of cytokines such as TNF-α, IL-1β, and IL-6. GPER antagonists can block these signaling processes. Abbreviations: GPER, G protein-coupled estrogen receptor; AC, adenylyl cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; PLC, phospholipase C; PPI2, phosphatidylinositol-4,5-bisphosphate; IP3, inositol trisphosphate; DAG, diacylglycerol; PKC, protein kinase C; LKB1, liver kinase B1; CaMKKβ, calmodulin-dependent protein kinase kinase beta; AMPK, AMP-activated protein kinase; CPT1, carnitine palmitoyl transferase 1; PPARα, peroxisome proliferator-activated receptor alpha; FAS, fatty acid synthase; SREBP-1 C, sterol regulatory element-binding protein 1c; GLUT4, glucose transport protein 4; ERα, estrogen receptor α; ERβ, estrogen receptor β; CREB, cAMP-response element binding protein; Nrf2, nuclear factor erythroid 2-related factor 2; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; TNF-α, tumor necrosis factor alpha; IL-1β, interleukin-1 beta; IL-6, interleukin-6CC BY-NC-ND · PubMed Central
Fig. 3 Relationship between GPER and nutrient metabolism. GPER centrally interacts with signaling pathways such as the PI3K/AKT, MAPK, and AMPK pathways. It impacts glucose metabolism by regulating hepatic glucose metabolism and increasing insulin sensitivity. In protein metabolism, GPER affects protein synthesis and homeostasis. In lipid metabolism, GPER promotes lipolysis and fatty acid oxidation and inhibits lipogenesis. In calcium metabolism, it influences osteoblast and osteoclast functions. Regarding vitamins, GPER is linked to their metabolism and antioxidant enzyme activity. The arrows represent regulatory directions, revealing the role of GPER in these metabolic pathways. Abbreviations: VDR, vitamin D receptor; PPARα, peroxisome proliferator-activated receptor alpha
Fig. 3 Relationship between GPER and nutrient metabolism. GPER centrally interacts with signaling pathways such as the PI3K/AKT, MAPK, and AMPK pathways. It impacts glucose metabolism by regulating hepatic glucose metabolism and increasing insulin sensitivity. In protein metabolism, GPER affects protein synthesis and homeostasis. In lipid metabolism, GPER promotes lipolysis and fatty acid oxidation and inhibits lipogenesis. In calcium metabolism, it influences osteoblast and osteoclast functions. Regarding vitamins, GPER is linked to their metabolism and antioxidant enzyme activity. The arrows represent regulatory directions, revealing the role of GPER in these metabolic pathways. Abbreviations: VDR, vitamin D receptor; PPARα, peroxisome proliferator-activated receptor alphaCC BY-NC-ND · PubMed Central
Fig. 4 The roles of GPER in metabolic diseases. At its core, GPER exerts a far-reaching influence on insulin-related processes. It impacts insulin signaling pathways, glucose metabolism, and insulin sensitivity, which are central to the development of T2D. Disruptions in these pathways can lead to insulin resistance, a hallmark of T2D. In bone metabolism, GPER affects the balance between osteoclast-driven bone resorption and osteoblast-mediated bone formation. This process is regulated through the RANKL-OPG axis, with implications for MBD. GPER also plays a role in the endocrine system. It influences TSH signaling, thereby affecting TH production. In the reproductive system, it affects androgen levels, ovarian function, and the hypothalamic‒pituitary‒ovarian axis, which are relevant to conditions such as PCOS. Moreover, GPER is involved in regulating oxidative stress. It activates pathways such as Nox1, MAPK, and NF-κB, which are associated with the generation of reactive oxygen species. These pathways, in turn, have implications for CVDs. Additionally, GPER affects adipose metabolism, including fatty acid oxidation and lipogenesis, which are linked to NAFLD and MS. Abbreviations: T2D, type 2 diabetes; MBD, metabolic bone disease; RANKL, receptor activator of nuclear factor κB ligand; OPG, osteoprotegerin; TD, thyroid disease; TSH, thyroid-stimulating hormone; TH, thyroid hormone; PCOS, polycystic ovary syndrome; LHRH, luteinizing hormone-releasing hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; CVDs, cardiovascular diseases; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; Nox1, NADPH oxidase 1; NAFLD, nonalcoholic fatty liver disease; MS, metabolic syndrome; IRS, insulin receptor substrate
Fig. 4 The roles of GPER in metabolic diseases. At its core, GPER exerts a far-reaching influence on insulin-related processes. It impacts insulin signaling pathways, glucose metabolism, and insulin sensitivity, which are central to the development of T2D. Disruptions in these pathways can lead to insulin resistance, a hallmark of T2D. In bone metabolism, GPER affects the balance between osteoclast-driven bone resorption and osteoblast-mediated bone formation. This process is regulated through the RANKL-OPG axis, with implications for MBD. GPER also plays a role in the endocrine system. It influences TSH signaling, thereby affecting TH production. In the reproductive system, it affects androgen levels, ovarian function, and the hypothalamic‒pituitary‒ovarian axis, which are relevant to conditions such as PCOS. Moreover, GPER is involved in regulating oxidative stress. It activates pathways such as Nox1, MAPK, and NF-κB, which are associated with the generation of reactive oxygen species. These pathways, in turn, have implications for CVDs. Additionally, GPER affects adipose metabolism, including fatty acid oxidation and lipogenesis, which are linked to NAFLD and MS. Abbreviations: T2D, type 2 diabetes; MBD, metabolic bone disease; RANKL, receptor activator of nuclear factor κB ligand; OPG, osteoprotegerin; TD, thyroid disease; TSH, thyroid-stimulating hormone; TH, thyroid hormone; PCOS, polycystic ovary syndrome; LHRH, luteinizing hormone-releasing hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; CVDs, cardiovascular diseases; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; Nox1, NADPH oxidase 1; NAFLD, nonalcoholic fatty liver disease; MS, metabolic syndrome; IRS, insulin receptor substrateCC BY-NC-ND · PubMed Central
Fig. 5 GPER regulation of the energy balance. GPER maintains energy homeostasis by differentially regulating metabolic activity in BAT and WAT. In BAT, GPER drives nonshivering thermogenesis via UCP1 and synergistically enhances fatty acid oxidation and heat production with estrogen ERα and ERβ. WAT serves as an energy storage depot and secretes a variety of metabolic hormones and cytokines. Moreover, GPER not only improves energy homeostasis by promoting browning but also inhibits inflammatory responses to increase the overall metabolic rate. Specifically, GPER promotes ATP synthesis through the direct activation of mitochondrial energy metabolism, oxidative phosphorylation and the PI3K/AKT and MAPK/ERK signaling pathways. In addition, GPER-mediated phosphorylation of AMPK could improve metabolic efficiency precisely. This multidimensional regulatory network reveals the central role of GPER in energy homeostasis. Abbreviations: BAT, brown adipose tissue; WAT, white adipose tissue; UCP1, uncoupling protein 1
Fig. 5 GPER regulation of the energy balance. GPER maintains energy homeostasis by differentially regulating metabolic activity in BAT and WAT. In BAT, GPER drives nonshivering thermogenesis via UCP1 and synergistically enhances fatty acid oxidation and heat production with estrogen ERα and ERβ. WAT serves as an energy storage depot and secretes a variety of metabolic hormones and cytokines. Moreover, GPER not only improves energy homeostasis by promoting browning but also inhibits inflammatory responses to increase the overall metabolic rate. Specifically, GPER promotes ATP synthesis through the direct activation of mitochondrial energy metabolism, oxidative phosphorylation and the PI3K/AKT and MAPK/ERK signaling pathways. In addition, GPER-mediated phosphorylation of AMPK could improve metabolic efficiency precisely. This multidimensional regulatory network reveals the central role of GPER in energy homeostasis. Abbreviations: BAT, brown adipose tissue; WAT, white adipose tissue; UCP1, uncoupling protein 1CC BY-NC-ND · PubMed Central
Fig. 6 GPER and tumor metabolism. GPER coordinates the multifaceted role of metabolic reprogramming in the tumor microenvironment. Glycolytic metabolism generates lactic acid via GLUTs/HK/LDH, which helps tumor cells evade immune surveillance and enhances their invasive ability. Furthermore, GPER regulates glycolytic metabolism in tumor cells by stabilizing the expression of HIF-1α. Fatty acid metabolism has dual dynamic functions: β-oxidation drives energy production, with fatty acid biosynthesis providing lipid components. Analyses of amino acid metabolism have highlighted distinct roles for BCAAs (BCKDH downregulation promotes breast and ovarian cancer progression and inhibits gastric and colorectal cancer progression) and glutamate (enhances the energy status and metabolic capacity). Studies of the microenvironment revealed that hypoxia may regulate GPER expression by feedback; acidic conditions inhibit GPER signaling but enhance metabolic adaptations, and the inflammatory factor TNF-α can promote glycolysis and fatty acid synthesis by activating the NF-κB signaling pathway. Drug resistance suggests that the estrogen/GPER/PKA signaling axis in CAFs mediates the synthesis and secretion of lactic acid and glutamine, leading to multidrug resistance in tumor cells. Abbreviations: GLUTs, glucose transporters; HK, hexokinase; LDH, lactate dehydrogenase; HIF-1α, hypoxia-inducible factor 1 alpha; BCAAs, branched-chain amino acids; BCKDH, branched-chain α-ketoacid dehydrogenase complex; CAFs, cancer-associated fibroblasts
Fig. 6 GPER and tumor metabolism. GPER coordinates the multifaceted role of metabolic reprogramming in the tumor microenvironment. Glycolytic metabolism generates lactic acid via GLUTs/HK/LDH, which helps tumor cells evade immune surveillance and enhances their invasive ability. Furthermore, GPER regulates glycolytic metabolism in tumor cells by stabilizing the expression of HIF-1α. Fatty acid metabolism has dual dynamic functions: β-oxidation drives energy production, with fatty acid biosynthesis providing lipid components. Analyses of amino acid metabolism have highlighted distinct roles for BCAAs (BCKDH downregulation promotes breast and ovarian cancer progression and inhibits gastric and colorectal cancer progression) and glutamate (enhances the energy status and metabolic capacity). Studies of the microenvironment revealed that hypoxia may regulate GPER expression by feedback; acidic conditions inhibit GPER signaling but enhance metabolic adaptations, and the inflammatory factor TNF-α can promote glycolysis and fatty acid synthesis by activating the NF-κB signaling pathway. Drug resistance suggests that the estrogen/GPER/PKA signaling axis in CAFs mediates the synthesis and secretion of lactic acid and glutamine, leading to multidrug resistance in tumor cells. Abbreviations: GLUTs, glucose transporters; HK, hexokinase; LDH, lactate dehydrogenase; HIF-1α, hypoxia-inducible factor 1 alpha; BCAAs, branched-chain amino acids; BCKDH, branched-chain α-ketoacid dehydrogenase complex; CAFs, cancer-associated fibroblastsCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 286 references

Research works printed but not linked: 3

  1. Sirizi MAG, Esmailidehaj M, Mohamadi-Zarch SM, et al. Cardioprotective effects of Gper agonist in ovariectomized diabetic rats: reversing Er stress and structural changes. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(3):2855–65. https://doi.org/10.1007/s00210-024-03438-4. · DOI
  2. Pepermans RA, Sharma G, Prossnitz ER. G protein-coupled estrogen receptor in cancer and stromal cells: functions and novel therapeutic perspectives. Cells. 2021. https://doi.org/10.3390/cells10030672. · DOI
  3. Gupta A, Shinde PG, Jorvekar S, et al. G protein-coupled oestrogen receptor regulates branched-chain amino acid metabolism through c-jun n-terminal kinase. FEBS Lett. 2025. https://doi.org/10.1002/1873-3468.70030. · DOI

Cited by

See all 16

Metadata

Authors
Liu, L., Zhou, Y., Liu, J., Zhang, X., He, C., Zeng, X., Dejenie, R., Zeb, U., Zeng, Q., Liu, L., Li, J., Zeng, X., Hu, Q., Huang, X., Xu, X., Dong, H., Zhong, J., Huang, Y., Lv, Q., Liu, B., Qiu, Y.-A., & Yu, T.
Affiliations
  • Jiangxi Provincial Cancer Hospital (CN)
  • Jiangxi University of Traditional Chinese Medicine (CN)
  • Nanchang University (CN)
  • Nanchang Medical College (CN)
  • University of Chicago Medical Center (US)
  • The University of Agriculture, Peshawar (PK)
Corresponding author
  • Liu, Bo
  • Yu, Tenghua
Venue
Journal of Translational Medicine
Published
2025-08-26
Volume
23
Issue
1
Pages
960-960
ISSN
1479-5876 (ISSN-L)
OpenAlex
W4413658314
Cited by
13
References
284
Citations by year
2026: 12 · 2025: 1
FWCI
1.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82160565, 82260565)
  • Major Discipline Academic and Technical Leaders Training Program of Jiangxi Province (20232BCJ23035)
  • Education Department of Jiangxi Province (GJJ2203532)
  • General Project of Jiangxi Provincial Administration of Traditional Chinese Medicine (2023B1281)
  • Open Research Fund of Jiangxi Cancer Hospital & Institute (2021J16)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
G protein-coupled estrogen receptor, metabolic homeostasis, nutrient metabolism, glucose metabolism, lipid metabolism, protein metabolism, type 2 diabetes, non-alcoholic fatty liver disease, metabolic syndrome, cardiovascular disease, thyroid dysfunction, energy balance, thermogenesis, cancer metabolism, metabolic disease treatment
MeSH terms
Animals, Energy Metabolism, Homeostasis, Humans, Metabolic Diseases, Receptors, Estrogen, Signal Transduction, Receptors, G-Protein-Coupled

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GPER in metabolic homeostasis and disease: molecular mechanisms, nutritional regulation, and therapeutic potential. https://app.cochat.ai/papers/10.1186/s12967-025-07005-0
The paper
Liu, L., Zhou, Y., Liu, J., Zhang, X., He, C., Zeng, X., Dejenie, R., Zeb, U., Zeng, Q., Liu, L., Li, J., Zeng, X., Hu, Q., Huang, X., Xu, X., Dong, H., Zhong, J., Huang, Y., Lv, Q., . . . Yu, T. (2025). GPER in metabolic homeostasis and disease: molecular mechanisms, nutritional regulation, and therapeutic potential. Journal of Translational Medicine. https://doi.org/10.1186/s12967-025-07005-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.